News

Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...
Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...